Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1990 Mar;116(2):203–206. doi: 10.1007/BF01612678

Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin

Ulrike Metz-Kurschel 1,✉, Erhard Kurschel 2, Norbert Niederle 2, Eberhard Aulbert 2
PMCID: PMC12201804  PMID: 2182639

Abstract

In order to detect even subclinical hints of nephrotoxicity after application of carboplatin, sensitive non-invasive methods, e.g. determination of urinary enzyme (lactate dehydrogenase, leucine aminopeptidase,γ-glutamyltransferase,N-acetyl-β-glucosaminidase), glomerular and tubular protein excretion (albumin,α-1-microglobulin) and determination of the creatinine clearance, were used. Eighteen patients with small-cell lung cancer entered the study. All patients were treated with the three-drug combination chemotherapy: vincristine (1.5 mg i.v. on days 1, 8, 15, 22), etopside (escalating doses: 100–160 mg/m2 on days 1–3) and carboplatin (300 mg/m2 day 1). Investigations were made during the first, third and fifth treatment cycles. Deterioration of renal function occurred in 4 out of 18 patients in all three observed treatment courses. Abnormal amounts in the excretion of at least one of four urinary enzymes were found in 6 out of 18 patients during the first cycle and in 4 out of 8 patients during the third and fifth cycles. All patients with pathological enzymuria during the first treatment course also developed an increased enzymuria during cycles 3 and 5. Four patients developed pathological proteinuria during the first and 2 patients during the third and fifth cycles. These findings demonstrate that the new platinum analogue, carboplatin, is capable of inducing renal damage. In comparison with cisplatinum, the nephrotoxicity of this new analogue is reduced but not completely eliminated.

Key words: Urinary enzymes, Protein excretion, Nephrotoxicity, Carboplatin

References

  1. Buamah PK, Howell A, Whitby H, Harpur S, Gescher A (1982) Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol 8:281–284 [DOI] [PubMed] [Google Scholar]
  2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum. II. Cancer Chemother Pharmacol 9:140–147 [DOI] [PubMed] [Google Scholar]
  3. Calvert AH, Horwich A, Newlands ES, Begent R, Rustin GJS, Kaye SB, Harris AL, Williams CJ, Slevin L (1988) Carboplatin or cisplatin? Lancet 2:577–578 [DOI] [PubMed] [Google Scholar]
  4. Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12:125–136 [DOI] [PubMed] [Google Scholar]
  5. Cohen AI, Harberg J, Citrin DL (1981) Measurement of urinaryβ2-microglobulin in the detection of cis-platin nephrotoxicity. Cancer Treat Rep 65:1083–1085 [PubMed] [Google Scholar]
  6. Curt AG, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) A phase I and pharmacokinetic study of diamminecyclobutanedicarboxylatoplatin (NSC 241240). Cancer Res 43:4470–4473 [PubMed] [Google Scholar]
  7. Diener U, Knoll E, Langer B, Rautenstrauch H, Ratge B, Wisser H (1981) Urinary excretion ofN-acetyl-β-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta 112:149–157 [DOI] [PubMed] [Google Scholar]
  8. Gore ME, Calvert AH, Smith IE (1987) High-dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalating study. Eur J Cancer Res Clin Oncol 23:1391–1397 [DOI] [PubMed] [Google Scholar]
  9. Groth S, Nielsen H, Sorensen B, Christensen B, Pedersen AG, Rorth M (1986) Acute and longterm nephrotoxicity ofcis-platinum in man. Cancer Chemother Pharmacol 17:191–196 [DOI] [PubMed] [Google Scholar]
  10. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44:1693–1697 [PubMed] [Google Scholar]
  11. Jones BR, Bhalla RB, Mladek J, Kalcya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Rcidcnberg NW (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 4:557–562 [DOI] [PubMed] [Google Scholar]
  12. Maruhn D, Fuchs I, Mues G (1976) Normal limits of urinary excretion of eleven enzymes. Clin Chem 22:1567–1574 [PubMed] [Google Scholar]
  13. Maruhn D, Strozyk K, Gielow L (1977) Diurnal variations of urinary enzyme excretions. Clin Chim Acta 75:427–433 [DOI] [PubMed] [Google Scholar]
  14. Metz U, Kurschel E, Graben N (1985) Monitoring renal toxicity of cis-platinum by urinary enzymes. Proc EDTA 22:1087–1090 [Google Scholar]
  15. Mitrou PS, Mondorf W (1979) Cis-Platin-Ncphrotoxizität: Effekt auf die proximalen Nierentubuli gemessen an der Ausscheidung der Alaninaminopeptidase(AAP) im Urin. In: Seeber S, Schmidt CG, Nagel G, Achterrath W (Hrsg) Cisplatin derzeitiger Stand und neue Entwicklungen in der Chemotherapie maligner Neoplasien. Karger, Basel München Paris London New York Sidney, pp 34–44 [Google Scholar]
  16. Mulder POM, Sleijfer DT, de Vries EGE, Uges DRA (1988) Renal dysfunction following high-dose carboplatin treatment. Eur J Cancer Res Clin Oncol 114:211–214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Osman N, Copley MP, Litterst CL (1984) Effects of the diuretics mannitol or acetazolamide on the nephrotoxicity and physiological disposition of cisplatin in rats. Cancer Chemother Pharmacol 13:58–62 [DOI] [PubMed] [Google Scholar]
  18. Ozols RF, Jacob J, Welsley MN, Ostega Y, Young RC (1984) High-dose Cisplatin in hypertonic saline. Ann Int Med 100:19–24 [DOI] [PubMed] [Google Scholar]
  19. Rose WC, Schurig JE (1985) Preclinical antitumor and toxicological profile of carboplatin. Cancer Treat Rev 12:1–19 [DOI] [PubMed] [Google Scholar]
  20. Skillen AW, Buamah PK, Cantwell BNJ, Cornell C, Hodson AW, Harris AL (1988) Urinary protein and enzyme excretion in patients receiving chemotherapy with thecis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM 9). Cancer Chemother Pharmacol 22:228–234 [DOI] [PubMed] [Google Scholar]
  21. Van Echo DA, Egorin MJ, Whitacre MY, Olman EA, Aisner J (1984) Phase I clinical and pharmacological trial of carboplatin for 5 days. Cancer Treat Rep 68:1103–1114 [PubMed] [Google Scholar]
  22. Vogl SE, Zaravinos T, Kaplan BH, Wollner D (1981) Safe and effective two-hour regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II). Eur J Cancer 17:345–350 [DOI] [PubMed] [Google Scholar]
  23. Von Hoff DD (1987) Whither carboplatin? — A replacement for an alternative to cis-platin? J Clin Oncol 2:169–171 [DOI] [PubMed] [Google Scholar]
  24. Werner M, Maruhn D, Atoba M (1969) Use of gel filtration in the assay of urinary enzymes. J Chromatogr 40:254–257 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES